Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

The Association of Calcium-Phosphorus Product With the Severity of Cardiac Valves Failure in Patients Under Chronic Hemodialysis

The Association of Calcium-Phosphorus Product With the Severity of Cardiac Valves Failure in Patients Under Chronic Hemodialysis

Calcium-Phosphorus Product Is Associated with Adverse Prognosis in Hospitalized Patients with Heart Failure and Chronic Kidney Disease

Serum Magnesium Level and Cardiac Valve Calcification in Hemodialysis Patients

Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study

12. Correlation between Calcium Phosphate Product and Visit-to-Visit Blood Pressure Variability in Patients with Chronic Hemodialysis

Heart valve calcification and calcium x phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention

Progression of cardiovascular calcification in hemodialysis patients

Abstract 9958: Calcium-Phosphorus Product is Associated with Adverse Prognosis in Hospitalized Patients with Heart Failure and Chronic Kidney Disease

Cardiac valve calcification is associated with mortality in hemodialysis patients: a retrospective cohort study

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Comparison of CT acquired cardiac valvular calcification scores in hemodialysis and peritoneal dialysis patients undergoing open heart surgery

Comparison of CT acquired valvular calcification scores in hemodialysis vs peritoneal dialysis patients undergoing open heart surgery

Relationship of Phosphorus and Calcium-Phosphorus Product With Mortality in CKD

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Association of Serum Phosphorus Variability with Coronary Artery Calcification among Hemodialysis Patients

Risk factor analysis of calcification in aortic and mitral valves in maintenance peritoneal dialysis patients.

Serum Alkaline Phosphatase Level Predicts Cardiac Valve Calcification in Maintenance Hemodialysis Patients

Abnormal factors analysis of calcium-phosphorus metabolism disorder in maintenance hemodialysis patients

Cardiac Valve Calcification by Echocardiography Predicts Coronary Artery Calcium Scores in Dialysis Patients

Association between serum beclin 1 level and cardiac valvular calcification in hemodialysis patients